Zydus Lifesciences says FDA warning letter to injectable unit will not affect supply to US
The letter, received on August 30, 2024, identifies concerns related to current good manufacturing practices (cGMP), which are already under remediation by the company. Shares of Zydus Lifesciences Ltd ended at ₹1,113.50, up by ₹2, or 0.18%, on the BSE.
ZYDUSLIFE
BSE
General
Markets